This case demonstrates the critical role of JAK1 and JAK2 gene transcription in antifungal defense, particularly in patients receiving ruxolitinib therapy, a JAK1 and JAK2 inhibitor, for PV or myelofibrosis. This evidence concerns the gene JAK2 and acquired polycythemia vera.